Le Lézard
Classified in: Health
Subject: ANNUAL MEETINGS

Extendicare Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders and Board Changes


MARKHAM, Ontario, May 30, 2019 (GLOBE NEWSWIRE) -- Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) today announced the results of matters voted on at its annual and special shareholders' meeting held on May 30, 2019 (the "Meeting"), which included the election as directors of the Company of all of the nominees listed in its management information and proxy circular dated April 22, 2019 (the "Information Circular"). The voting results for each of the matters considered at the Meeting are presented below. 

The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 27,096,106, representing 30.56% of the Company's outstanding common shares.

1. Election of Directors
On a vote by a show of hands, the election of the following nine nominees as directors of the Company to hold office until the next annual meeting of the Company, or until their respective successors are elected or appointed, was approved. Proxies were received on this matter as follows:

NomineeVotes For%Votes Withheld
%
Norma Beauchamp25,555,23298.76321,163 1.24
Margery O. Cunningham25,556,97798.77319,418 1.23
Dr. Michael Guerriere25,606,93498.96269,461 1.04
Sandra L. Hanington25,570,55098.82305,845 1.18
Alan R. Hibben25,053,27596.82823,120 3.18
Donna E. Kingelin25,572,20698.82304,189 1.18
Samir Manji25,663,07899.18213,317 0.82
Al Mawani25,549,40698.74326,989 1.26
Alan D. Torrie25,606,29298.96270,103 1.04

2. Appointment of Auditors
On a vote by a show of hands, the appointment of KPMG LLP as the auditors of the Company until the next annual meeting of the Company to be held in the year 2020 was approved. Proxies were received on this matter as follows:

Votes For%Votes Withheld
%
26,662,18398.68355,669 1.32

3. Approval of all Unallocated Securities, Rights or Other Entitlements under Extendicare's Long Term Incentive Plan
On a vote by a show of hands, the ordinary resolution to approve all unallocated securities, rights or other entitlements under Extendicare's Long Term Incentive Plan was approved. Proxies were received on this matter as follows:

Votes For%Votes Against
%
24,800,51495.841,075,881 4.16

4. Approach to Executive Compensation
On a vote by a show of hands, a non-binding advisory resolution to accept the Company's approach to executive compensation disclosed in the Company's Information Circular was approved. Proxies were received on this matter as follows:

Votes For%Votes Against%
25,081,15596.93795,2403.07

Board Changes

As previously announced, Gail Paech did not stand for re-election at the Meeting. Extendicare's management team and its board of directors (the "Board") thanks Gail for her exemplary service and the significant contributions she made during her tenure as a director.

The Board and management welcome two new directors ? Samir Manji and Norma Beauchamp ? who bring an impressive and diverse range of expertise to the Extendicare team.

ABOUT EXTENDICARE

Extendicare is a leading provider of care and services for seniors across Canada. We are committed to delivering quality care throughout the health continuum to meet the needs of a growing seniors population. We operate a network of 122 senior care and retirement living centres (68 owned/54 managed) and home health care services under the Extendicare, Esprit Lifestyle and ParaMed brands. Our qualified and highly trained workforce of approximately 23,000 individuals is passionate about providing high quality services to help people live better.

For further information, contact:

Jillian Fountain
Vice President, Investor Relations
Phone:  (905) 470-5534; Fax: (905) 470-4003
Email:  [email protected]
Visit Extendicare's Website at www.extendicare.com

 


These press releases may also interest you

at 16:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments....

at 16:05
Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to...

at 16:05
Personalis, Inc. , a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time. About Personalis, Inc....

at 16:05
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December...

at 16:05
Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial...

at 16:05
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023...



News published on and distributed by: